Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novelion Therapeutics Inc.

www.novelion.com

Latest From Novelion Therapeutics Inc.

Welcome To Alexion 2.0

In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.

C-Suite Speaks Outlook 2020

Interview: Amryt Aims High After Aegerion Acquisition

The Irish firm's CEO told Scrip about a transformative deal for Amryt, creating an international business with revenues of nearly $140m.

M & A Rare Diseases

Deal Watch: Ireland's Amryt Acquires Aegerion

European firms Amryt and Evotec have signed agreements to acquire two companies based across the Atlantic – Aegerion and Just Biotherapeutics, respectively. 

Deals M & A

Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma

Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • QLT Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Novelion Therapeutics Inc.
  • Senior Management
  • Ben Harshbarger, Interim CEO
    Michael Price, EVP, CFO
  • Contact Info
  • Novelion Therapeutics Inc.
    Phone: (617) 500-7867
    1800 - 510 West Georgia St.
    Vancouver, V6B 0M3
    Canada
UsernamePublicRestriction

Register